Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo

European Journal of Cancer

Volumn 35, Issue 9, 1999, Pages 1394-1401

  Gu, W Z ^a   Tahir, S K ^a   Wang, Y C ^a   Zhang, H C ^a   Cherian, S P ^a   O'Connor, S ^a   Leal, J A ^a   Rosenberg, S H ^a   Ng, S C ^a  

^a Cancer Research   (United States)

Author keywords

Angiogenesis; Farnesyltransferase inhibitor (FTI); Ras; Vascular endothelial growth factor (VEGF)

Indexed keywords

A 170634; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ALKYL AND ARYL TRANSFERASES; ANIMALS; COLONIC NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; FARNESYLTRANSTRANSFERASE; HUMANS; LYMPHOKINES; METHIONINE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; PYRIDINES; RATS; TUMOR CELLS, CULTURED; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033198180     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00132-X     Document Type: Article

References (41)

1. Barbacid M. Ras genes. Ann. Rev. Biochem. 56:1987;779-827.
2. Medema R.H., Bos J.L. The role of p21 Ras in receptor tyrosine kinase signaling. Crit. Rev. Oncol. 4:1993;615-661.
3. McCormick F. How receptors turn Ras on. Nature. 363:1993;15-16.
4. James G.L., Goldstein J.L., Brown M.S.et al. Benzodiazepine peptidomimetics. potent inhibitors of Ras farnesylation in animal cells Science. 260:1993;1937-1942.
5. Bollag G., McCormick F. Regulators and effectors of Ras proteins. Ann. Rev. Cell. Biol. 7:1991;601-632.
6. Lowy D.R., Willumsen B.M. Function and regulation of Ras. Ann. Rev. Biochem. 62:1993;851-891.
7. Conn G., Bayne M.L., Soderman D.D.et al. Amino acid and cDNA sequences of a vascular endothelial cell mitogen that is homologous to platelet-derived growth factor. Proc. Natl. Acad. Sci. 87:1990;2628-2632.
8. Rak J.N., St Croix B., Kerbel R.S. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anti-Cancer Drugs. 6:1995;3-18.
9. Rak J., Filmus J., Finkenzeller G., Grugel S., Marmé D., Kerbel R.S. Oncogenes as inducers of tumor angiogenesis. Cancer Metas. Rev. 14:1995;263-277.
10. Hancock J.F., Paterson H., Marshall C.J. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21 ras to the plasma membrane. Cell. 63:1990;133-139.
11. Kato K., Cox A.D., Hisaka M.M.et al. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc. Natl. Acad. Sci. 89:1992;6403-6407.
12. Willumsen B.M., Christensen A., Hubbert N.C., Papagerge A.C., Lowy D.R. The p21 ras C-terminus is required for transformation and membrane association. Nature. 310:1984;583-586.
13. ras farnesyltransferase. J. Biol. Chem. 269:1994;12410-12413.
14. Hancock J.F. Anti-Ras drugs come of age. Curr. Biol. 3:1993;770-772.
15. Sepp-Lorenzino L., Ma Z., Rands E.et al. A peptidomimetic inhibitor of farnesyl: protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 55:1995;5302-5309.
16. Claffey K.P., Brown L.F., Aguila L.F.et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 56:1996;172-182.
17. Rak J., Kerbel R.S. Treating cancer by inhibiting angiogenesis. new hopes and potential pitfalls Cancer Metas. Rev. 15:1996;231-236.
18. Grugel S., Finkenzeller G., Weindel K., Barleon B., Marmé D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem. 270:1995;25915-25919.
19. Dvorak H.F., Brown L., Detmar M., Dovrak A. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Path. 146:1995;1029-1038.
20. D'Amore P.A., Shima D.T. Tumor angiogenesis: a physiological process or genetically determined? Cancer Metas. Rev. 15:1996;205-212.
21. Folkman J. Anti-angiogenesis. new concept for therapy of solid tumors Ann. Surg. 175:1972;409-416.
22. Kim K.J., Li B., Winer J.et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 362:1993;841-844.
23. Millauer B., Shawver L.K., Risau W., Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature. 367:1994;576-579.
24. Lerner E.C., Qian Y., Blaskovich M.A.et al. Ras CAAX peptidomimetic FTI-277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive ras-raf complexes. J. Biol. Chem. 270:1995;26802-26806.
25. Schnaper H.W., Grant D.S., Stetler-Stevenson W.G.et al. Type IV collagenases and TIMPs modulate endothelial cell morphogenesis in vitro. J. Cell Physiol. 156:1993;235-246.
26. Polverini PJ, Bouck NP, Rastinejad F. Assay and purification of naturally occurring inhibitor of angiogenesis. In Barnes D, Mather JP, Sato GH. Methods in Enzymology. San Diego Academic Press, 1991, 440-450.
27. Kenyon B.M., Voest E.E., Chen C.C., Flynn E., Folkman J., D'Amato R.J. A model of angiogenesis in the mouse cornea. Invest. Ophth. Vis. Sci. 37:1996;1625-1632.
28. White F.C., Carroll S.M., Kamps M.P. VEGF mRNA is reversibly stabilized by hypoxia and persistently stabilized in VEGF-overexpressing human tumor cell lines. Growth Factors. 12:1995;289-301.
29. Rak J., Mitsuhashi Y., Erdos V., Huang S.N., Filmus J., Kerbel R.S. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression. J. Cell Biol. 131:1995;1587-1598.
30. Lebowitz P.F., Sakamuro D., Prendergast G.C. Farnesyl transferase inhibitors induce apoptosis of ras-transformed cells denied substratum attachment. Cancer Res. 57:1997;708-713.
31. Barrington R.E., Subler M.A., Rands E.et al. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol. Cell Biol. 18:1998;85-92.
32. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. 91:1994;4082-4085.
33. Alon T., Hemo I., Itin A., Pe'er J., Stone J., Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Medicine. 1:1995;1024-1028.
34. Rak J., Mitsuhashi Y., Bayko L., Filmus J., Sasazuki T., Kerbel R.S. Mutant ras oncogenes upregulate VEGF/VPF expression. implications for induction and inhibition of tumor angiogenesis Cancer Res. 55:1995;4575-4580.
35. Warren R.S., Yuan H., Mati M.R., Gillett N.A., Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95:1995;1789-1797.
36. Brown L.F., Berse B., Jackman R.W.et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res. 53:1993;4727-4735.
37. Lebowitz P.F., Prendergast G.C. Non-Ras targets of farnsyltransferase inhibitors. focus on Rho Oncogene. 17:1998;1439-1445.
38. Johnson L., Greenbaum D., Cichowski K.et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Develop. 11:1997;2468-2481.
39. Fox P.L., Sa G., Dobrowolski S.F. The regulation of endothelial cell motility by p21 ras. Oncogene. 9:1994;3519-3526.
40. Du W., Lebowitz P.F., Prendergast G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol. 19:1999;1831-1840.
41. Cox A.D., Der C.J. Farnesyltransferase inhibitors and cancer treatement. targeting simply Ras? Biochim. Biophys. Acta. 1333:1997;F51-71.